基础磷脂治疗乙醇性肝病45例  

The Effect of Essential Phospholipids in the Treatment of Alcoholic Hepatopathy

作　　者：甘雪婷[1] 白宪光[1] 罗红[1] 

机构地区：[1]第四军医大学唐都医院感染病中心,西安710038

出　　处：《医药导报》2003年第6期392-393,共2页Herald of Medicine

摘　　要：目的 :探讨基础磷脂注射液治疗乙醇性肝病的疗效及安全性。方法 :45例乙醇性肝病患者均给予基础磷脂注射液 5 0 0mg ,加入 5 %或 10 %葡萄糖注射液 2 5 0mL中缓慢静脉滴注 ,qd ,并辅以其他综合治疗 ,疗程 8周 ;所有病例均在治疗前及治疗结束后进行常规体检 (包括肝脾B超检查 ) ,肝肾功能以及血清肝纤维化指标透明质酸 (HA)、Ⅲ型前胶原氨基端肽 (PⅢP)的检测。结果 :治疗结束时 ,显效率 5 7.8% ,有效率 2 8.9% ,无效率 13 .3 %。结论 :基础磷脂注射液是一种治疗乙醇性肝病安全而有效的药物。Objective:To study the therapeutic effectiveness and safety rate of essential phospholipids (EPL) in the treatment of alcoholic hepatopathy. Methods:45 patients with alcoholic hepatopathy were given each 500 mg of EPL injection in 250 mL of 5% or 10% glucose solution administered by slow IV instillation q.d., supplemented with routine supportive measures. The course of treatment lasted 8 weeks. All patients were subjected to routine physical examination, assay of liver function and liver fibrosis indices including hyaluronic acid and PⅢP before and after the termination of treatment. Results:At the termination of the treatment, the rate of excellent clinical response was 57.8%(26/45), that of moderate improvement 28.9%(13/45) and only 6 patients (13.3%) were unaffected. Conclusion:EPL was shown to be a safe and effective drug in the treatment of alcoholic hepatopathy.

关 键 词：基础磷脂 乙醇性肝病 

分 类 号：R977.6[医药卫生—药品] R575.1[医药卫生—药学]